Tan Jackson, Khalil Muhammad Abdul Mabood, Tan Si Yen, Khalil Muhammad, Ahmed Dalinatul, Zinna Shaukat, Chong William
RIPAS Hospital, Bandar Seri Begawan BA1710, Brunei Darussalam.
Aga Khan University Hospital, Karachi 74800, Pakistan.
J Transplant. 2014;2014:784805. doi: 10.1155/2014/784805. Epub 2014 Nov 12.
Objectives. Brunei Darussalam has a high prevalence and incidence of end stage renal disease (ESRD). Up until 2012, all renal transplantations were performed in overseas centres, either as government-sponsored (living-related transplantation) or as self-sponsored (commercialized transplantation) ones. We hypothesize that graft and patient survival of Brunei renal transplant patients are on a par with international standards. Materials and Methods. Data of all renal transplant patients in Brunei were analysed over a twenty-year period from registry records and case notes. Comparative survival data from other countries were obtained from PubMed-listed literature. Results. A total of 49 transplantation procedures were performed in foreign centres between 1993 and 2012. 29 were government-sponsored and 20 were self-sponsored transplantations. The 5- and 10-year overall patient survival rates were 93.3% and 90.1%, respectively. The 5- and 10-year overall graft survival rates were 91.1% and 81.2%. There is no difference in the survival outcomes of government-sponsored and self-sponsored patients. Living-related (government-sponsored) and commercialised (self-sponsored) grafts had equivalent survival to those reported in the literature. Conclusion. Our survival data was on par with those achieved in many countries. We hope to use this information to convince local stakeholders and patients to favour transplantation as the preferred modality of RRT.
目标。文莱达鲁萨兰国终末期肾病（ESRD）的患病率和发病率很高。直到2012年，所有肾移植手术均在海外中心进行，要么是政府资助的（亲属活体移植），要么是自费的（商业化移植）。我们假设文莱肾移植患者的移植物和患者存活率与国际标准相当。材料与方法。通过登记记录和病例记录，分析了文莱所有肾移植患者在20年期间的数据。其他国家的比较生存数据来自PubMed列出的文献。结果。1993年至2012年期间，在国外中心共进行了49例移植手术。29例为政府资助，20例为自费移植。患者的5年和10年总生存率分别为93.3%和90.1%。移植物的5年和10年总生存率分别为91.1%和81.2%。政府资助和自费患者的生存结果没有差异。亲属活体（政府资助）和商业化（自费）移植物的存活率与文献报道的相当。结论。我们的生存数据与许多国家的相当。我们希望利用这些信息来说服当地利益相关者和患者，使其倾向于将移植作为首选的肾脏替代治疗方式。
